Core Viewpoint - Zhejiang Sandar Biopharmaceutical Co., Ltd. has approved the use of idle raised funds for cash management, allowing for an investment of up to RMB 23 million in low-risk financial products to enhance fund efficiency and returns for shareholders [2][12]. Investment Overview - **Investment Purpose**: The aim is to improve the efficiency of raised funds and increase returns for the company and its shareholders while ensuring that the investment does not affect the construction and use of the raised funds [4]. - **Investment Amount**: The total amount for cash management is RMB 8 million [5]. - **Source of Funds**: The funds for cash management come from temporarily idle funds raised through a specific stock issuance [6]. - **Basic Situation of Raised Funds**: The company raised a total of RMB 267.61 million through the issuance of 17,840,666 shares at RMB 15 per share, with a net amount of RMB 261.42 million after deducting issuance costs [7]. Investment Products - **Investment Method**: The cash management products include structured deposits and large certificates of deposit, with a focus on high safety and liquidity [10]. - **Investment Duration**: The cash management is valid for 12 months from the date of board approval [11]. Review Procedures - The board and supervisory committee meetings held on July 7, 2025, approved the cash management proposal, which does not require shareholder meeting approval and is valid for 12 months [12]. Impact on the Company - The use of idle funds for cash management will not affect the company's normal operations or the ongoing investment projects, and it aims to enhance the efficiency of fund usage and increase returns for shareholders [15].

Core Viewpoint - The company has announced the progress of cash management using idle raised funds, with a total amount of RMB 100 million approved for cash management activities [1][2][3] Group 1: Cash Management Details - The entrusted party for cash management is China Construction Bank [1] - The amount redeemed for cash management is RMB 100 million [1] - The board approved the use of idle raised funds for cash management on July 25, 2024, with a total limit of RMB 50 million, valid from August 19, 2024, to August 18, 2025 [1][3] Group 2: Financial Performance - The company has utilized RMB 10 million for cash management, with an actual annualized return of 1.26%, resulting in earnings of RMB 65.72 thousand [1] - In the last twelve months, the total amount of idle raised funds used for cash management was RMB 97 million, with an actual recovery amount of RMB 77 million and total earnings of RMB 361.13 thousand [2] - The highest single-day investment in the last twelve months was RMB 45 million, which is 2.36% of the audited net assets for the past year [2]